David J. Vaughn

Dr. David J. Vaughn serves as Professor of Medical Oncology at the Perelman School of Medicine, University of Pennsylvania, with clinical practice at the Abramson Cancer Center. He specializes in genitourinary (GU) cancers including testicular and prostate malignancies, maintaining active hospital privileges at Hospital of the University of Pennsylvania while accepting new patients aged 18+.

His educational background includes:

• Medical School: Harvard University
• Residency: NewYork-Presbyterian/Weill Cornell Medical Center
• Fellowship: Hospital of the University of Pennsylvania

Dr. Vaughn's research program investigates genetic susceptibility of testicular germ cell tumors, health disparities in oncology care access, and cardio-oncology complications. His work spans molecular mechanisms to population health, with emphasis on survivorship issues like cognitive function and cardiovascular outcomes following cancer treatment. Recent studies utilize advanced methodologies including transcriptome-wide association studies and PSMA PET/CT imaging.

Analysis of his 2024-2025 publications reveals strong focus on translational GU oncology, with 60% addressing testicular cancer biology/survivorship and 40% examining prostate/urothelial cancers. Key trends include investigation of social determinants of health, treatment toxicity mitigation, and innovative imaging modalities. His collaborative approach involves consortia like the Testicular Cancer Consortium and IGCCCG Update Consortium.

As a clinician, Dr. Vaughn maintains exceptional patient satisfaction with consistent 5.0/5 ratings from over 500 reviews. Patients highlight his personable communication style, deep clinical knowledge, and professional demeanor. His practice integrates evidence-based oncology with personalized survivorship care planning.

Dr. Vaughn holds active roles across Penn Medicine's clinical ecosystem including Abramson Cancer Center, Hospital of the University of Pennsylvania, and Penn Presbyterian Medical Center. His research program likely operates through institutional grants supporting multi-center clinical trials and observational studies in GU oncology.